EIF2A and chronic myelogenous leukemia, BCR-ABL1 positive: Meanwhile, genetic modification of CML cells via transfection with dominant-negative mutants of PERK or dominant-negative eIF2α-S51A mutant, results in markedly increased levels of apoptosis when treated with imatinib (127).